第十二届儿科药物开发战略论坛:CDK抑制剂在儿童及青少年肿瘤中的研发共识
第十二届多利益相关方儿科战略论坛聚焦细胞周期蛋白依赖性激酶(CDK)抑制剂,评估其在儿童及青少年恶性肿瘤中的研发策略。论坛指出CDK4/6抑制剂单药客观缓解罕见、缺乏预测生物标志物且试验设计重复,建议以临床前明确肿瘤退缩而非仅细胞静止作为推进决策点,并优先开展联合策略。CDK9/12/13抑制剂在MYCN驱动神经母细胞瘤等临床前模型中显示前景,应序贯协调开发并早期接触监管机构。
要点
- CDK4/6抑制剂在儿童肿瘤中客观缓解罕见,缺乏预测生物标志物,试验设计存在重复。
- 推进临床研究应以临床前明确肿瘤退缩而非仅细胞静止作为go/no go决策点。
- 新抑制剂应避免单药暴露,快速推进联合策略并保留早期活性评估设计。
核心结论
- 儿童恶性肿瘤中CDK4/6抑制剂的进一步开发需要优先排序与协调。
- 应以临床前明确肿瘤退缩而非仅细胞静止作为推进临床研究的go/no go决策点。
- 基于临床前单药活性有限,新抑制剂试验应避免不必要的单药暴露并快速推进联合策略。
研究设计与样本
- 第十二届多利益相关方儿科战略论坛,由ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与,聚焦CDK抑制剂。
主要发现
- 儿童肿瘤中CDK4/6通路因遗传异常而活性增加,成为治疗靶点,CDK4/6抑制剂已在儿童及年轻患者中单药及联合评估,包括ESMART中的分子富集。
- CDK4/6抑制剂临床前数据主要显示细胞静止而非肿瘤退缩,客观缓解罕见,但可能延缓肿瘤生长。
- 与成人相似,未识别预测生物标志物,且缺乏该类药物的整合综合临床开发策略。
- 患者倡导者认为CDK4/6抑制剂众多试验入组大量儿童和年轻人,但知识收获不相匹配。
- CDK9、CDK12和CDK13抑制剂基于转录易感性在MYCN驱动神经母细胞瘤、骨肉瘤和易位融合驱动恶性肿瘤的临床前模型中显示前景。
临床怎么用
- CDK9/12/13抑制剂的开发应序贯、迭代和协调,包括早期与监管机构接触。
- 新抑制剂试验应避免不必要的单药暴露,快速推进联合策略,同时保留允许早期活性评估的设计。
- 支持跨申办方整合开发策略的框架将非常有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The twelfth multi-stakeholder Paediatric Strategy focused on cyclin-dependent kinase (CDK) inhibitors. Genetic aberrations in paediatric tumours increase CDK4/6 activity, thus the pathway is a therapeutic target. As a result, CDK4/6 inhibitors have been evaluated in clinical trials for children and young adults with different malignancies, both as single agents and in combination, including molecular enrichment in ESMART. In some instances, trials of different agents within this same class are very similar in design or target population, leading to duplication. Consistent with preclinical data with CDK4/6 inhibitors which mostly demonstrate cytostasis, but not tumour regression, objective responses are rare, although there may be slowing of tumour growth. Similar to adults, no predictive biomarkers have been identified and an integrated comprehensive clinical development strategy of this class of agents is lacking. Patient advocates believe that the many trials of CDK4/6 inhibitors, which have enrolled many children and young people, have not been matched by sufficient gains in knowledge. CDK9, CDK12 and CDK13 inhibitors, based on exploitation of transcriptional vulnerabilities, have shown promise in preclinical models of MYCN-driven neuroblastoma, osteosarcoma and translocation fusion-driven malignancies. The development of these inhibitors should be sequential, iterative and coordinated, including early engagement with regulators. In conclusion, there needs to be prioritisation and coordination of any further development of CDK4/6 inhibitors in paediatric malignancies. Definite tumour regression in preclinical models, not just cytostasis, should be taken as the go/no go decision point to progress such agents to clinical studies. Based on limited single agent activity in preclinical models, trials of new inhibitors should avoid unnecessary exposure of patients to monotherapy and rapidly progress to combination strategies, while retaining designs that allow early evaluation of activity. A framework to support integrated development strategies of new products across sponsors would be very beneficial.
引用
- Pearson AD, Chi S, Laetscht TW, et al. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration. Eur J Cancer. 2025. PMID: 40680434. doi:10.1016/j.ejca.2025.115629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。